 |
Diseases |  |
Trials |
|
Trials |  |
News |  |
| «12345678910» |
- imipenem/relebactam / Merck (MSD), Vabomere (meropenem/vaborbactam) / Melinta Therap, Zavicefta (ceftazidime/avibactam) / Pfizer, AbbVie
Carbapenemase Producing Serratia Marcescens: Persistent In The Environment And Resistant In The Patient (Exhibit and Poster Hall) - Jun 4, 2022 - Abstract #ASMMicrobe2022ASM_Microbe_2468;
Despite availability of novel beta-lactamase inhibitors the majority of isolates developed resistance after treatment. It will be critical to consider how additional carbapenemase producing species may respond to new antimicrobial combinations and monitor for the development of resistance after exposure to the new agents.
- | imipenem/relebactam / Merck (MSD), Zavicefta (ceftazidime/avibactam) / Pfizer, AbbVie
Journal: Dynamic evolution of imipenem/relebactam resistance in a KPC-producing Klebsiella pneumoniae from a single patient during ceftazidime/avibactam-based treatments. (Pubmed Central) - Jun 4, 2022
Our results show the in vivo evolution of genetic rearrangement conferring resistance to imipenem/relebactam in a patient with KPC-Kp infection and treated with different ceftazidime/avibactam-based treatments. The rapid development of mutations and the high adaptability of its genome highlight the potential threat of KPC-Kp.
- || Review, Journal: Drug Regimens of Novel Antibiotics in Critically Ill Patients with Varying Renal Functions: A Rapid Review. (Pubmed Central) - May 30, 2022
However, there are limited data on the topic. The aim of this review was therefore to summarize available PK studies on these novel antibiotics performed in patients with ARC or AKI, or requiring RRT, in order to provide a practical approach to guide clinicians in the choice of the best dosage regimens in critically ill patients.
- || imipenem/relebactam / Merck (MSD), Vabomere (meropenem/vaborbactam) / Melinta Therap, Zavicefta (ceftazidime/avibactam) / Pfizer, AbbVie
Review, Journal: Resistance to Ceftazidime/Avibactam, Meropenem/Vaborbactam and Imipenem/Relebactam in Gram-Negative MDR Bacilli: Molecular Mechanisms and Susceptibility Testing. (Pubmed Central) - May 30, 2022
Lastly, we described and discussed the main detection methods for antimicrobial susceptibility testing of such molecules. With increasing reports of resistance to novel βL-βLICs, continuous attention should be maintained on the monitoring of the phenotypic traits of MDR pathogens, into the characterization of related mechanisms, and on the emergence of cross-resistance to these novel antimicrobials.
- || Zerbaxa (ceftolozane /tazobactam) / Merck (MSD), imipenem/relebactam / Merck (MSD)
Review, Journal: Use of Novel Antibiograms to Determine the Need for Earlier Susceptibility Testing and Administration for New β-Lactam/β-Lactamase Inhibitors in the United States. (Pubmed Central) - May 30, 2022
Novel antibiograms such as syndromic antibiograms that incorporate resistant gram-negative phenotypes and/or minimum inhibitory concentration distributions may assist in determining the need for earlier susceptibility testing or help define an earlier optimal use of the new β-lactam/β-lactamase inhibitors. The purpose of this review is to emphasize novel antibiogram approaches that are capable of improving the time to susceptibility testing and administration for new β-lactam/β-lactamase inhibitors so that they are earlier in a patient's treatment course.
- imipenem/relebactam / Merck (MSD), Vabomere (meropenem/vaborbactam) / Melinta Therap
Pkpqil Trac Mutation Increases Plasmid Copy Number, Kpc-3 Production and Carbapenem Mics in the Presence of Kpc Inhibitors Against Klebsiella Pneumoniae (AAR Track Hub) - May 21, 2022 - Abstract #ASMMicrobe2022ASM_Microbe_2130;
We concluded, therefore, that this mutation in traC, modifying a proline, which is highly likely to affect structure of a known essential protein for plasmid conjugation, increases plasmid copy number, thereby increasing KPC-3 production and conferring carbapenem/KPC inhibitor resistance. This is the first time that traC mutations have been associated with increased copy number for any plasmid, and the exact mechanism for this remains to be determined.
- imipenem/relebactam / Merck (MSD), Vabomere (meropenem/vaborbactam) / Melinta Therap, Zavicefta (ceftazidime/avibactam) / Pfizer, AbbVie
Impact of Ompk36 Genotype and Kpc Subtype on the In Vitro Activity of Ceftazidime-Avibactam, Imipenem-Relebactam, and Meropenem-Vaborbactam Against Kpc-producing K. Pneumoniae Clinical Isolates (Exhibit and Poster Hall) - May 21, 2022 - Abstract #ASMMicrobe2022ASM_Microbe_1507;
Addition of CST preferentially improved in vitro killing for MEV and IMR against isolates with porin mutations. Our findings suggest that these agents may not be interchangeable for treatment of KPC-Kp infections, warranting further investigation.
- imipenem/relebactam / Merck (MSD), Vabomere (meropenem/vaborbactam) / Melinta Therap, Zavicefta (ceftazidime/avibactam) / Pfizer, AbbVie
Detection of the Carbapenem-Hydrolyzing CTX-M-15 Variant, CTX-M-33, Among Carbapenem-Nonsusceptible Klebsiella Pneumoniae Isolates from Poland (Exhibit and Poster Hall) - May 21, 2022 - Abstract #ASMMicrobe2022ASM_Microbe_1445;
This is the case of the CTX-M15 derivative CTX-M-33 that was observed in 4 isolates from Poland. Other carbapenem resistance mechanisms were present in the isolates producing this enzyme.
- Overcoming β-Lactam and Multi-Drug Resistance in Pseudomonas Aeruginosa Through a Novel β-Lactam/β-Lactam Enhancer Combination: A Step Beyond β-Lactam/β-Lactamase Inhibitors (Salon GHI) - May 21, 2022 - Abstract #ASMMicrobe2022ASM_Microbe_241;
MICs of cefepime/zidebactam (FEP/ZID, a BL/BLE) and novel BL/BLIs were determined against a selected panel (n=113) of MDR PSA...Among the subset of non-carbapenemase producing strains (79/113), susceptibilities (CLSI criteria) to ceftolozane/tazobactam, cefepime/taniborbactam, ceftazidime/avibactam, and imipenem/relebactam were 54, 52, 51, and 61%, respectively while FEP/ZID, inhibited 92.4% at 8 mg/L...The BL/BLE, FEP/ZID combination demonstrated comprehensive activity in vitro and translational in vivo efficacy against strains with FEP/ZID MICs up to 32 mg/L (a concentration inhibiting 100% of PSAs). BLE mechanism of FEP/ZID potentially offers a novel paradigm in managing infections caused by present and future MDR PSA clones.
- | imipenem/relebactam / Merck (MSD), Vabomere (meropenem/vaborbactam) / Melinta Therap
Journal: Increased bla Copy Number and OmpK35 and OmpK36 Porins Disruption Mediated Resistance to Imipenem/Relebactam and Meropenem/Vaborbactam in a KPC-Producing Klebsiella pneumoniae Clinical Isolate. (Pubmed Central) - May 20, 2022
Imipenem/relebactam-resistance was associated to meropenem-vaborbactam cross-resistance and was due to truncated OmpK35 and OmpK36 porins and increased copy of bla copy number. Genome analysis demonstrated that imipenem/relebactam-resistant KPC-Kp harbored a second copy of bla-carrying Tn4401 in a ColRNAI plasmid as a consequence of a transposition event.
- | imipenem/relebactam / Merck (MSD)
Journal: Imipenem/Relebactam Resistance in Clinical Isolates of Extensively Drug Resistant Pseudomonas aeruginosa: Inhibitor-Resistant β-Lactamases and Their Increasing Importance. (Pubmed Central) - May 20, 2022
The poor inhibition by REL of the GES β-lactamases (GES-2, -19, and -20; apparent K of 19 ± 2 μM, 23 ± 2 μM, and 21 ± 2 μM, respectively) within the isolates also contributed to the observed IMI/REL-resistant phenotype. Modeling of REL binding to the active site of GES-20 suggested that the acylated REL is positioned in an unstable conformation as a result of a constrained Ω-loop.
- | Zerbaxa (ceftolozane /tazobactam) / Merck (MSD), imipenem/relebactam / Merck (MSD), Zavicefta (ceftazidime/avibactam) / Pfizer, AbbVie
Preclinical, Journal: In Vitro Activity of Ceftolozane-Tazobactam, Imipenem-Relebactam, Ceftazidime-Avibactam, and Comparators against Pseudomonas aeruginosa Isolates Collected in United States Hospitals According to Results from the SMART Surveillance Program, 2018 to 2020. (Pubmed Central) - May 20, 2022
Most P. aeruginosa isolates were C/T-susceptible, including many with MDR, pan-β-lactam-nonsusceptible, DTR, CZA-resistant, and IMR-nonsusceptible phenotypes. While C/T was the most active antipseudomonal agent, IMR demonstrated greater activity than CZA against isolates nonsusceptible to C/T.
- | imipenem/relebactam / Merck (MSD)
Journal, Combination therapy: Aztreonam in combination with imipenem-relebactam against clinical and isogenic strains of serine and metallo-β-lactamase-producing enterobacterales. (Pubmed Central) - May 12, 2022
While C/T was the most active antipseudomonal agent, IMR demonstrated greater activity than CZA against isolates nonsusceptible to C/T. Aztreonam plus imipenem-relebactam may be a viable treatment option for aztreonam-non-susceptible NDM and serine β-lactamase-producing E. coli and K. pneumoniae.
- | Zerbaxa (ceftolozane /tazobactam) / Merck (MSD), imipenem/relebactam / Merck (MSD), Zavicefta (ceftazidime/avibactam) / Pfizer, AbbVie
Journal: Combination of phage therapy and cefiderocol to successfully treat Pseudomonas aeruginosa cranial osteomyelitis. (Pubmed Central) - May 10, 2022
This report adds to the growing literature that phage therapy may be a safe and effective approach to augment antibiotic therapy for patients infected with drug-resistant pathogens. Furthermore, it highlights the importance of the GES β-lactamase family in contributing to inactivation of a broad range of β-lactam antibiotics in P. aeruginosa, including ceftolozane/tazobactam, ceftazidime/avibactam and imipenem/relebactam.
- | imipenem/relebactam / Merck (MSD), Vabomere (meropenem/vaborbactam) / Melinta Therap, Zavicefta (ceftazidime/avibactam) / Pfizer, AbbVie
Preclinical, Journal: In vitro activity of imipenem-relebactam activity against KPC-producing Klebsiella pneumoniae resistant to ceftazidime-avibactam and/or meropenem-vaborbactam. (Pubmed Central) - May 6, 2022
Furthermore, it highlights the importance of the GES β-lactamase family in contributing to inactivation of a broad range of β-lactam antibiotics in P. aeruginosa, including ceftolozane/tazobactam, ceftazidime/avibactam and imipenem/relebactam. No abstract available
- imipenem/relebactam / Merck (MSD)
In vivo evolution of imipenem/relebactam resistance in KPC-producing Klebsiella pneumoniae isolated from a critically ill patient () - May 2, 2022 - Abstract #ECCMID2022ECCMID_4570;
- | imipenem/relebactam / Merck (MSD)
Preclinical, Journal: In Vitro Antibacterial Activity of Imipenem/Relebactam against Clinical Isolates in Japan. (Pubmed Central) - Apr 30, 2022
The antibacterial activity of IMR against imipenem-nonsusceptible P. aeruginosa isolates was lower than that of AMK but comparable to or higher than those of other drugs. These results support the use of IMR as a new treatment option for infections due to Enterobacterales and P. aeruginosa strains that are resistant to existing β-lactams and other antibacterial agents.
- ||| Zerbaxa (ceftolozane /tazobactam) / Merck (MSD), imipenem/relebactam / Merck (MSD)
Pray to any God willing to listen. What do you have access to? Ceftolozane-tazobactam maybe imipenem-relebactam , or cefiderocol also depending where the infection is. I have never been in the situation of using bacteriophage @a_hamprecht @OncIDPharmd @ClancyNeil @davidvanduin (Twitter) - Apr 27, 2022
- || PK/PD data, Review, Journal: Microbiological, Clinical, and PK/PD Features of the New Anti-Gram-Negative Antibiotics: β-Lactam/β-Lactamase Inhibitors in Combination and Cefiderocol-An All-Inclusive Guide for Clinicians. (Pubmed Central) - Apr 24, 2022
Considering the complexity of summarizing and integrating the emerging literature data of clinical outcomes, microbiological mechanisms, and pharmacokinetic/pharmacodynamic properties of the new BL/BLI and cefiderocol, we aimed to provide an overview of data on the following compounds: aztreonam/avibactam, cefepime/enmetazobactam, cefepime/taniborbactam, cefepime/zidebactam, cefiderocol, ceftaroline/avibactam, ceftolozane/tazobactam, ceftazidime/avibactam, imipenem/relebactam, meropenem/nacubactam and meropenem/vaborbactam. Each compound is described in a dedicated section by experts in infectious diseases, microbiology, and pharmacology, with tables providing at-a-glance information.
- | imipenem/relebactam / Merck (MSD)
Journal: Successful Treatment of Bloodstream Infection due to a KPC-Producing Klebsiella Pneumoniae Resistant to Imipenem/Relebactam in a Hematological Patient. (Pubmed Central) - Apr 24, 2022
Although treatment with CAZ-AVI and gentamicin completely eradicated the infection due KPC-Kp cross-resistance to IMI-REL and MER-VAB, the patient became colonized subsequently by KPC-Kp strains susceptible to IMI-REL and MER-VAB...Phylogenetic analysis demonstrated that KPC-Kp cross-resistance to IMI-REL and MER-VAB was clonally related to a KPC-Kp resistant to IMI-REL as previously described, demonstrating the spread of this multidrug resistant clone in the hematological unit. In conclusion, the results presented in this study reported the emergence of cross-resistance to MER-VAB and IMI-REL in a KPC-Kp strain isolated from a hematological patient and highlight the potential development and diffusion of new multidrug resistance traits.
- | Journal: Klebsiella pneumoniae Mutants Resistant to Ceftazidime-Avibactam Plus Aztreonam, Imipenem-Relebactam, Meropenem-Vaborbactam, and Cefepime-Taniborbactam. (Pubmed Central) - Apr 22, 2022
The V239G variant does not generate collateral β-lactam susceptibility like many KPC-3 variants associated with ceftazidime-avibactam resistance. Additional mutation of ompK35 and production of the OXA-48-like carbapenemase OXA-232 were required to confer cefepime-taniborbactam resistance.
- | Journal: Impact of Acquired Broad-Spectrum β-Lactamases on Susceptibility to Cefiderocol and Newly Developed β-Lactam/β-Lactamase Inhibitor Combinations in Escherichia coli and Pseudomonas aeruginosa. (Pubmed Central) - Apr 22, 2022
The ability of broad-spectrum β-lactamases to reduce the susceptibility to ceftazidime-avibactam (CZA), ceftolozane-tazobactam (C/T), imipenem-relebactam, meropenem-vaborbactam, aztreonam-avibactam (AZA), and cefiderocol (FDC) was evaluated both in Pseudomonas aeruginosa and in Escherichia coli using isogenic backgrounds. Although metallo-β-lactamases conferred resistance in most cases, except for AZA, several clavulanic-acid-inhibited extended-spectrum β-lactamases (PER, BEL, SHV) had a significant impact on the susceptibility to CZA, C/T, and FDC.
- | Journal: New Antibiotics for Hospital-Acquired Pneumonia and Ventilator-Associated Pneumonia. (Pubmed Central) - Apr 21, 2022
The approved antibiotics include ceftobiprole, ceftolozane-tazobactam, ceftazidime-avibactam, meropenem-vaborbactam, imipenem-relebactam, and cefiderocol. Their major advantages include their high activity against multidrug-resistant gram-negative pathogens.
- | Preclinical, Journal: In vitro antibacterial activity of cefiderocol against recent multidrug-resistant carbapenem-nonsusceptible Enterobacterales isolates. (Pubmed Central) - Apr 14, 2022
Susceptibility for comparators ranged from 24.0% for meropenem to 91.3%, 92.3% and 96.1% for imipenem-relebactam, ceftazidime-avibactam and meropenem-vaborbactam, respectively; 48.1%, 75.2% and 79.8% of the isolates were susceptible to omadacycline, colistin and eravacycline, respectively. Two isolates with cefiderocol MICs of 2 mg/L had mutations or deletions of the iron transport genes fhuA/E or fepA, as determined by WGS.
- | Zerbaxa (ceftolozane /tazobactam) / Merck (MSD), imipenem/relebactam / Merck (MSD)
Preclinical, Journal: Comparative analysis of in vitro dynamics and mechanisms of ceftolozane/tazobactam and imipenem/relebactam resistance development in Pseudomonas aeruginosa XDR high-risk clones. (Pubmed Central) - Apr 2, 2022
Two isolates with cefiderocol MICs of 2 mg/L had mutations or deletions of the iron transport genes fhuA/E or fepA, as determined by WGS. Imipenem/relebactam could be a useful alternative for the treatment of XDR P. aeruginosa infections, potentially reducing resistance development during therapy.
- || imipenem/relebactam / Merck (MSD)
Trial completion: Imipenem-Relebactam Pharmacokinetics in Augmented Renal Clearance (clinicaltrials.gov) - Mar 31, 2022
P1, N=9, Completed, Sponsor: Hartford Hospital
Imipenem/relebactam could be a useful alternative for the treatment of XDR P. aeruginosa infections, potentially reducing resistance development during therapy. Recruiting --> Completed
- Zerbaxa (ceftolozane /tazobactam) / Merck (MSD), imipenem/relebactam / Merck (MSD), Zavicefta (ceftazidime/avibactam) / Pfizer, AbbVie
Activity of imipenem/relebactam and cefiderocol against clinical and laboratory Pseudomonas aeruginosa isolates expressing blaPDC and blaOXA-type β-lactamases that confer resistance to ceftolozane/tazobactam and ceftazidime/avibactam () - Mar 28, 2022 - Abstract #ECCMID2022ECCMID_2662;
- imipenem/relebactam / Merck (MSD), Zavicefta (ceftazidime/avibactam) / Pfizer, AbbVie
Comparative in vitro dynamics and resistance mechanisms to Imipenem/Relebactam and Ceftazidime/Avibactam in high-risk clones of KPC-2 and KPC-3-producing Klebsiella pneumoniae () - Mar 28, 2022 - Abstract #ECCMID2022ECCMID_2660;
- imipenem/relebactam / Merck (MSD)
Klebsiella pneumoniae susceptibility to imipenem/relebactam and doripenem/relebactam combinations: role of inoculum density and carbapenem-to-inhibitor concentration ratio () - Mar 28, 2022 - Abstract #ECCMID2022ECCMID_2586;
- imipenem/relebactam / Merck (MSD)
In vitro activity of imipenem/relebactam against Pseudomonas aeruginosa isolates recovered from ICU patients with UTIs, IAIs and LRTIs in Spain and Portugal (SUPERIOR and STEP studies) () - Mar 28, 2022 - Abstract #ECCMID2022ECCMID_2540;
- imipenem/relebactam / Merck (MSD)
In vitro imipenem/relebactam and comparators susceptibility of Enterobacterales isolates recovered from ICU patients with UTIs, IAIs and LRTIs in Portugal and Spain: STEP and SUPERIOR studies () - Mar 28, 2022 - Abstract #ECCMID2022ECCMID_2527;
- Zerbaxa (ceftolozane /tazobactam) / Merck (MSD), imipenem/relebactam / Merck (MSD)
Activity of ceftolozane/tazobactam and imipenem/relebactam against clinical Pseudomonas aeruginosa isolates from Lebanon and Jordan: SMART 2017-2020 () - Mar 28, 2022 - Abstract #ECCMID2022ECCMID_2502;
- imipenem/relebactam / Merck (MSD), Zavicefta (ceftazidime/avibactam) / Pfizer, AbbVie
Association of blaKPC and blaNDM in ceftazidime/avibactam and imipenem/relebactam resistant Enterobacterales in Brazil () - Mar 28, 2022 - Abstract #ECCMID2022ECCMID_2498;
- Zerbaxa (ceftolozane /tazobactam) / Merck (MSD), imipenem/relebactam / Merck (MSD)
Activity of ceftolozane/tazobactam and imipenem/relebactam against clinical Gram-negative isolates from Czech Republic, Hungary, and Poland: SMART 2017-2020 () - Mar 28, 2022 - Abstract #ECCMID2022ECCMID_2488;
- imipenem/relebactam / Merck (MSD)
Probability of simultaneous coverage of KPC-producing Enterobacterales and carbapenem-resistant P. aeruginosa: a comparison of imipenem/relebactam with other agents in South Korea and Taiwan: SMART 2017-2020 () - Mar 28, 2022 - Abstract #ECCMID2022ECCMID_2486;
- Zerbaxa (ceftolozane /tazobactam) / Merck (MSD), imipenem/relebactam / Merck (MSD)
Susceptibility and cross-susceptibility of imipenem/relebactam and ceftolozane/tazobactam against Gram-negative isolates from South Korea and Taiwan: SMART 2018-2020 () - Mar 28, 2022 - Abstract #ECCMID2022ECCMID_2485;
- Zerbaxa (ceftolozane /tazobactam) / Merck (MSD), imipenem/relebactam / Merck (MSD)
Activity of ceftolozane/tazobactam and imipenem/relebactam against multidrug-resistant Pseudomonas aeruginosa isolates collected in western Europe: SMART 2017-2020 () - Mar 28, 2022 - Abstract #ECCMID2022ECCMID_2480;
- imipenem/relebactam / Merck (MSD)
In vitro activity of imipenem/relebactam against KPC-encoding Enterobacterales from six European countries in 2018-2020 () - Mar 28, 2022 - Abstract #ECCMID2022ECCMID_2479;
- Zerbaxa (ceftolozane /tazobactam) / Merck (MSD), imipenem/relebactam / Merck (MSD)
Antimicrobial susceptibility to ceftolozane/tazobactam, imipenem/relebactam and comparators among Gram-negative isolates collected from ICU patients in Latin America, SMART 2016-2020 () - Mar 28, 2022 - Abstract #ECCMID2022ECCMID_2476;
- imipenem/relebactam / Merck (MSD)
Activity of imipenem/relebactam against meropenem-non-susceptible clinical Enterobacterales and Pseudomonas aeruginosa isolates from different regions: SMART 2020 () - Mar 28, 2022 - Abstract #ECCMID2022ECCMID_2414;
- | Preclinical, Journal: Epidemiology and in vitro activity of ceftazidime-avibactam, meropenem-vaborbactam, imipenem-relebactam, eravacycline, plazomicin, and comparators against Greek carbapenemase-producing Klebsiella pneumoniae isolates. (Pubmed Central) - Mar 26, 2022
Novel BLBLIs, eravacycline, and plazomicin are promising agents for combating infections by carbapenemase-producing K. pneumoniae. However, the emergence of resistance to these agents highlights the need for continuous surveillance and application of enhanced antimicrobial stewardship.
- | cefepime/taniborbactam (cefepime/VNRX-5133) / VenatoRx
Preclinical, Journal: In vitro activity of cefepime-taniborbactam against carbapenemase producing Enterobacterales and Pseudomonas aeruginosa isolates recovered in Spain. (Pubmed Central) - Mar 24, 2022
isolates (163/170, MIC>2 mg/L), activity of FTB against serine-β-lactamase (35/163) and MBL producers (43/163) was 88.6% and 65.1%, respectively, whereas the susceptibility of comparators was: ceftazidime-avibactam, 88.5% and 16.0%; meropenem-vaborbactam, 8.5% and 7.0%; imipenem-relebactam, 2.9% and 2.3%; ceftolozane-tazobactam, 0% and 2.3%; and piperacillin-tazobactam, 0% and 0%, respectively. Microbiological results suggest FTB as a potential therapeutic option in patients infected with carbapenemase-producing Enterobacterales and carbapenem-resistant Pseudomonas isolates, including MBL producers.
- || Review, Journal: Antimicrobial Treatment Options for Difficult-to-Treat Resistant Gram-Negative Bacteria Causing Cystitis, Pyelonephritis, and Prostatitis: A Narrative Review. (Pubmed Central) - Mar 24, 2022
Here, we provide a narrative review on the clinical and pre-clinical studies of drugs that can be used for difficult-to-treat resistant Gram-negative bacteria, with a particular focus on data relevant to the urinary tract. We also offer a pragmatic framework for antibiotic selection when encountering urinary tract infections due to difficult-to-treat resistant Gram-negative bacteria based on the organism and its mechanism of resistance.
- | imipenem/relebactam / Merck (MSD)
New trial: Phenotypic Profile and Molecular Mechanism of Resistance in Carbapenemase-producing Enterobacterales and Pseudomonas Aeruginosa Isolates From Brazilian Hospitals: Implications for the Introduction of IMIPENEM-RELEBACTAM (clinicaltrials.gov) - Mar 16, 2022
P=N/A, N=250, Enrolling by invitation, Sponsor: D'Or Institute for Research and Education
- | imipenem/relebactam / Merck (MSD), Vabomere (meropenem/vaborbactam) / Melinta Therap
Journal: Non-susceptibilities to antibiotics against important Gram-negative bacteria, and imipenem-relebactam, meropenem-vaborbactam against carbapenem non-susceptible Enterobacterales and Pseudomonas aeruginosa isolates implicated in complicated intra-abdominal and urinary tract infections in Taiwan, 2019. (Pubmed Central) - Mar 16, 2022
We also offer a pragmatic framework for antibiotic selection when encountering urinary tract infections due to difficult-to-treat resistant Gram-negative bacteria based on the organism and its mechanism of resistance. Continuous monitoring of susceptibility to clinically important GNB is warranted.
- || imipenem/relebactam / Merck (MSD)
One more Becka SA, Zeiser ET, LiPuma JJ, Papp-Wallace KM. Activity of Imipenem-Relebactam against Multidrug- and Extensively Drug-Resistant Burkholderia cepacia Complex and Burkholderia gladioli. Antimicrob Agents Chemother. 2021 Oct 18;65(11):e0133221. doi: 10.1128/AAC.01332-21. (Twitter) - Mar 16, 2022
- | imipenem/relebactam / Merck (MSD), relebactam (MK-7655) / Merck (MSD)
Journal: Activity of imipenem/relebactam on Klebsiella pneumoniae with different mechanisms of imipenem non-susceptibility. (Pubmed Central) - Mar 1, 2022
Relebactam activity against isolates harbouring-bla or with altered Ompk35 & Ompk36 gene expression and efflux pump hyperactivity need further studies. Therefore, using IMP/R antibiotic in the treatment of infections caused by IMP/NS K. pneumoniae should be based on its molecular profile of IMP resistance to optimize the utility of IMP/R.
- | imipenem/relebactam / Merck (MSD), Vabomere (meropenem/vaborbactam) / Melinta Therap, Zavicefta (ceftazidime/avibactam) / Pfizer, AbbVie
Preclinical, Journal: Assessment of In Vitro Cefiderocol Susceptibility and Comparators against an Epidemiologically Diverse Collection of Acinetobacter baumannii Clinical Isolates. (Pubmed Central) - Feb 26, 2022
Cefiderocol-resistance was higher among carbapenem-resistant isolates and isolates belonging to ST2, but could not be associated with any particular resistance mechanism or clonal lineage. Our data suggest that cefiderocol is a good alternative to treat infections caused by MDR A. baumanni, including carbapenem-resistant strains.
- || colistin sulphate / Generic mfg.
Review, Journal: The Role of Colistin in the Era of New β-Lactam/β-Lactamase Inhibitor Combinations. (Pubmed Central) - Feb 26, 2022
Nevertheless, colistin may be needed for the treatment of CRAB infections and in the setting where the new BLBLIs are currently unavailable. In addition, with the advent of rapid diagnostic methods and novel antimicrobials, the application of personalized medicine has gained significant importance in the treatment of CRE infections.